Baohua Zhao¹, Teng Zhang^2,*, Wenwen Liu², Fansong Meng², Chengben Liu¹, Nuo Chen², Zhi Li³, Zhaobin Liu³, Xiyou Li^2,*

Journal of Renewable Materials, Vol.11, No.4, pp. 1533-1554, 2023, DOI:10.32604/jrm.2022.023192 - 01 December 2022

Abstract

Due to the solution processable nature, the prepared perovskite films are polycrystalline with considerable number of defects. These defects, especially defects at interface accelerate the carrier recombination and reduce the carrier collection. Besides, the surface defects also affect the long-term stability of the perovskite solar cells (PVSCs). To solve this problem, surface passivation molecules are introduced at selective interface (the interface between perovskite and carrier selective layer). This review summarizes recent progress of small molecules used in PVSCs. Firstly, different types of defect states in perovskite films are introduced and their effects on device performance are

More > Graphic Abstract

Yangyang Hao, Yue Liu^*, Guorui Cao^*

Journal of Renewable Materials, Vol.10, No.12, pp. 3505-3519, 2022, DOI:10.32604/jrm.2022.023122 - 14 July 2022

Abstract Aiming to reduce the defects of perovskite film and improve carrier transport, an organic small molecule, benzo [d]isothiazol-3(2H)-one 1,1-dioxide (OBS), is introduced as an additive in the solution-processing of perovskite and prepare uniform perovskite films with a continuous distribution of OBS at grain boundaries. Fourier transform infrared spectroscopy and X-ray photoelectron spectroscopy are conducted to reveal the interactions of hydrogen bonding and coordination bonding between OBS and perovskite. Various characterizations (including X-ray diffraction, UV-vis spectroscopy, electrochemical impedance spectroscopy, etc.) are conducted to uncover the effect of OBS on device performance. Consequently, high efficiency of 23.26% More > Graphic Abstract

Daniel Dodzi Yao Setsoafia¹, Kiran Sreedhar Ram¹, Hooman Mehdizadeh-Rad^1,2, David Ompong^1,2, Vinuthaa Murthy^1,2, Jai Singh^1,2,*

Journal of Renewable Materials, Vol.10, No.10, pp. 2553-2567, 2022, DOI:10.32604/jrm.2022.020967 - 08 June 2022

Abstract DFT and TD-DFT calculations of HOMO and LUMO energies and photovoltaic properties are carried out on four selected pentathiophene donor and one IDIC-4F acceptor molecules using B3LYP and PBE0 functionals for the ground state energy calculations and CAM-B3LYP functional for the excited state calculations. The discrepancy between the calculated and experimental energies is reduced by correlating them with a linear fit. The fitted energies of HOMO and LUMO are used to calculate the V_oc of an OSC based on these donors and acceptor blend and compared with experimental values. Using the Scharber model the calculated PCE… More >

Qiuyun Luo^*†1, Wentao Pan^*†‡1, Suna Zhou^*†1, Guangfeng Wang^‡, Hanjie Yi^*§, Lin Zhang^*¶, Xianglei Yan^*†, Luping Yuan^*†, Zhenyi Liu^#, Jing Wang^**, Haibo Chen^#, MiaoZhen Qiu^*††, DaJun Yang^*†‡, Jian Sun^*‡‡

Oncology Research, Vol.28, No.4, pp. 331-344, 2020, DOI:10.3727/096504020X15825405463920

Abstract Despite therapeutic advances, the effective treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) remains a major clinical challenge. Evasion of apoptosis through upregulating antiapoptotic B-cell lymphoma-2 (BCL-2) family members and p53 inactivation, and abnormal activation of B-cell receptor signaling pathway are two important pathogenic factors for DLBCL. In this study, our aim is to explore a rational combination of BCL-2 inhibitor plus Bruton’s tyrosine kinase (BTK) blockade or p53 activation for treating DLBCL with the above characteristics. We demonstrated that a novel BCL-2 selective inhibitor APG-2575 effectively suppressed DLBCL with BCL-2 high expression… More >

MASOUMEH OGHABI^1,2, AVA SAFAROGHLI-AZAR^1,2, ATIEH POURBAGHERI-SIGAROODI^1,2, MOHAMMAD SAYYADI³, MOHSEN HAMIDPOUR¹, MOHAMMAD HOSSEIN MOHAMMADI¹, DAVOOD BASHASH^1,*

BIOCELL, Vol.44, No.2, pp. 183-192, 2020, DOI:10.32604/biocell.2020.08880 - 27 May 2020

Abstract Pathogenesis of chronic myeloid leukemia (CML) has mostly been studied with regard to the oncogenic role of BCR/ABL fusion; however, recent disclosures have declared that the challenges with the treatment of CML patients would not be resolved until the role of other aberrancies is ignored. Given the involvement of cyclin-dependent kinases (CDKs) in the pathogenesis of CML, the present study aimed to investigate the effects of a multi-CDK inhibitor AT7519 on BCR/ABL-harboring CML-derived K562 cells. Our results showed that AT7519 effectively reduced the survival of K562 and induced its anti-proliferative effect through the induction of… More >

Prasanna Rajagopalan^*†, Abdulrahim Hakami^*†, Mohammed Ragab^*, Ashraf Elbessoumy^*‡

Oncology Research, Vol.27, No.8, pp. 957-964, 2019, DOI:10.3727/096504019X15555428221646

Abstract Arylidene analogs are well proven for biological activities. FCY-302, a novel small molecule belonging to this class, was screened for its biological efficacy in leukemia and myeloma cells. FCY-302 selectively inhibited proliferation of cancer cells with GI50 values of 395.2 nM, 514.6 Nm, and 642.4 nM in HL-60, Jurkat, and RPMI-8226 cells, respectively. The compound also increased sub-G0 peak in the cancer cell cycle and favored apoptosis determined by annexin V assay. The compound decreased the antiapoptotic Bcl-2 levels and increased proapoptotic Bax proteins in leukemia and myeloma cell lines. FCY-302 attenuated the mitochondrial membrane-bound Na⁺ More >